Longeveron (LGVN) Times Interest Earned (2020 - 2026)
Longeveron (LGVN) posted quarterly Times Interest Earned of -$6.2 for Q1 2026, down 57.4% year-over-year from -$14.56 in Q1 2025, and up 2.02% quarter-over-quarter from -$6.33 in Q4 2025.
Longeveron (LGVN) Times Interest Earned (2020 - 2026) Analysis & Trends
Longeveron's Times Interest Earned history runs 7 years deep, the most recent figure standing at -$6.2 for Q1 2026.
- In Q1 2026, Times Interest Earned fell 57.4% year-over-year to -$6.2; the TTM figure through Mar 2026 stood at -$29.72 (down 121.88% YoY), while the FY2025 annual figure was -$22.11, down 2311.2% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$6.2, up from -$6.33 in the prior quarter.
- The five-year high for Times Interest Earned was $436.75 in Q4 2022, with the low at -$175.48 in Q4 2023.
- The 5-year median for Times Interest Earned is -$6.2 (2026), against an average of $2.17.
- The sharpest annual moves came in 2022 and 2024: Times Interest Earned surged 529957.65% in 2022, then slumped 14612.45% in 2024.
- Longeveron's Times Interest Earned stood at $436.75 in 2022, then sank by 140.18% to -$175.48 in 2023, then surged by 97.47% to -$4.44 in 2024, then sank by 42.67% to -$6.33 in 2025, then increased by 2.02% to -$6.2 in 2026.
- Business Quant data shows LGVN's Times Interest Earned at -$6.2 in Q1 2026, -$6.33 in Q4 2025, and -$4.98 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.65 |
| Mar 31, 2026 | -6.20 |
| Dec 31, 2025 | -6.33 |
| Sep 30, 2025 | -4.98 |
| Jun 30, 2025 | -3.82 |
| Mar 31, 2025 | -3.94 |
| Dec 31, 2024 | -4.44 |
| Sep 30, 2024 | -20.75 |
| Jun 30, 2024 | -74.47 |
| Mar 31, 2024 | -18.26 |
| Dec 31, 2023 | -175.48 |
| Sep 30, 2023 | -23.04 |
| Jun 30, 2023 | -24.00 |
| Mar 31, 2023 | -0.12 |
| Dec 31, 2022 | 436.75 |
| Sep 30, 2022 | -23.16 |
| Jun 30, 2022 | -6.01 |
| Mar 31, 2022 | -4.83 |
| Dec 31, 2021 | 0.08 |
| Sep 30, 2021 | -0.27 |